title: Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps.
abstract: We demonstrated the existence of three transport activities in promastigotes of Leishmania braziliensis, Leishmania guyanensis, and Leishmania mexicana. The first activity, an energy-dependent efflux of pirarubicin, was observed in all Leishmania species and inhibited by verapamil, by 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl-5-(trans-4,6-dimethyl-1, 3,2-dioxaphosphorinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-3-py ridinecarboxylate P oxide (PAK104P) and by the phenothiazine derivatives: thioridazine, prochlorperazine, trifluoperazine, chlorpromazine and trifluoropromazine. The second activity, an energy-dependent efflux of calcein acetoxymethylester, was observed in all Leishmania species and inhibited by PAK104P and the same phenothiazine derivatives, but not by verapamil. The third activity, an energy-dependent efflux of calcein, was clearly detected in L. braziliensis and guyanensis and inhibited only by prochlorperazine and trifluoperazine. The fact that prochlorperazine and trifluoperazine inhibited the energy-dependent efflux of the three substrates suggests that these activities are mediated by the same transport system. It is noteworthy that the transport system identified in this study shares several properties with the mammalian multidrug resistance pump, MRP1. Pirarubicin, calcein acetoxymethylester and calcein are well known substrates of the MRP. Furthermore, the three types of inhibitors are also inhibitors of the MRP function.
authors.affiliation: Laboratoire de Physicochimie Biomolëculaire et Cellulaire (UPRES-A 7033), Université Paris Nord, Bobigny, France.
authors.forename: M
authors.initials: M
authors.lastname: Essodaïgui
authors.forename: F
authors.initials: F
authors.lastname: Frézard
authors.forename: E S
authors.initials: ES
authors.lastname: Moreira
authors.forename: F
authors.initials: F
authors.lastname: Dagger
authors.forename: A
authors.initials: A
authors.lastname: Garnier-Suillerot
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D003498:Cyclic P-Oxides / Q000494:pharmacology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000378:metabolism; D018432:Drug Resistance, Multiple; D004734:Energy Metabolism; D005452:Fluoresceins / Q000378:metabolism*; D005456:Fluorescent Dyes / Q000378:metabolism; D007891:Leishmania / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D009539:Nicotinic Acids / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D003498:Cyclic P-Oxides; D005452:Fluoresceins; D005456:Fluorescent Dyes; D009539:Nicotinic Acids; D010640:Phenothiazines; C103821:PAK 104P; C085925:calcein AM; D004317:Doxorubicin; D014700:Verapamil; C027260:pirarubicin; C007740:fluorexon